Clinical trial · Observational
The Role of 18F-FDG and 68Ga-FAPI PET/CT in the Diagnosis and the Efficacy Evaluation of Advanced Colorectal Cancer (peritoneal Metastasis With/without Other Metastases)
NCT06601075CI-TRIAL-00084924recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to investigate the value of 18F-FDG and 68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of advanced colorectal cancer (peritoneal metastasis with/without other metastases)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Patients diagnosis of advanced colorectal cancer
- description
- Patients diagnosis of advanced colorectal cancer (peritoneal metastasis with/without other metastases)
Primary outcomes (3)
- measure
- Diagnostic accuracy
- timeFrame
- Baseline and up to 3 months
- description
- 18F-FDG and 68Ga-FAPI PET/CT was used to diagnose the lesions of the patients, and the diagnostic performance of PET/CT was evaluated by comparing the diagnostic results with the pathological results/clinical evaluation results.
- measure
- Standardized uptake value(SUV)
- timeFrame
- Baseline and up to 3 months
- description
- SUV of 68Ga-FAPI and 18F-FDG uptake on PET/CT images for tumor lesions
- measure
- Target-to-background ratio(TBR)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically confirmed colorectal cancer, clinical or other imaging suspicion of peritoneal metastasis with or without other distant metastases. 2. Patients voluntarily enrolled in this study by signing an informed consent form 3. Age ≥ 18 years 4. Expected life expectancy ≥ 3 months 5. Adequate organ and bone marrow function 6. Willingness to adhere to the study protocol and follow-up programme Exclusion Criteria: 1. Pregnant or breastfeeding women. 2. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix 3. Severe mental disease, uncontrolled epilepsy, or central nervous system disease 4. Subjects with current concurrent interstitial pneumonitis or interstitial lung disease, or subjects with previous interstitial pneumonitis or interstitial lung disease requiring hormonal therapy, or subjects with other conditions that may interfere with the judgement and management of immune-related pulmonary toxicity, e.g., pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pulmonary fibrosis, organising pneumonia (e.g., occlusive bronchiectasis), pneumoconiosis, Drug-associated pneumonia, idiopathic pneumonia, active pneumonia, or severe pulmonary impairment on CT; and active tuberculosis
References
Publications (0)
Data not yet available
No reference posted for this study.